Diplomat Pharmacy, Inc. (NYSE:DPLO) has been assigned a $16.00 target price by research analysts at Mizuho in a report released on Tuesday. The firm currently has a “hold” rating on the stock. Mizuho’s price target would indicate a potential downside of 24.31% from the company’s current price.

A number of other analysts have also recently commented on DPLO. BidaskClub cut Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research note on Thursday, June 29th. Zacks Investment Research cut Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. Needham & Company LLC started coverage on Diplomat Pharmacy in a research note on Friday, July 21st. They issued a “buy” rating and a $19.75 price target for the company. TheStreet raised Diplomat Pharmacy from a “d+” rating to a “c-” rating in a research note on Thursday, August 10th. Finally, Robert W. Baird reaffirmed a “buy” rating and issued a $20.00 price target on shares of Diplomat Pharmacy in a research note on Sunday, September 17th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $19.36.

Diplomat Pharmacy (DPLO) opened at 21.14 on Tuesday. The firm has a market cap of $1.44 billion, a PE ratio of 115.52 and a beta of 0.74. Diplomat Pharmacy has a 52 week low of $12.25 and a 52 week high of $26.44. The stock has a 50 day moving average of $20.24 and a 200 day moving average of $17.38.

Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings results on Monday, August 7th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.10. The company had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.14 billion. Diplomat Pharmacy had a return on equity of 7.97% and a net margin of 0.27%. Diplomat Pharmacy’s revenue was up 3.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.23 EPS. Analysts anticipate that Diplomat Pharmacy will post $0.75 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/25/mizuho-analysts-give-diplomat-pharmacy-inc-dplo-a-16-00-price-target.html.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Advisor Group Inc. increased its stake in Diplomat Pharmacy by 21.1% during the 3rd quarter. Advisor Group Inc. now owns 3,614 shares of the company’s stock worth $102,000 after purchasing an additional 629 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Diplomat Pharmacy by 73.1% during the 1st quarter. JPMorgan Chase & Co. now owns 7,235 shares of the company’s stock worth $116,000 after purchasing an additional 3,056 shares in the last quarter. State of Alaska Department of Revenue increased its stake in Diplomat Pharmacy by 80.0% during the 2nd quarter. State of Alaska Department of Revenue now owns 8,623 shares of the company’s stock worth $127,000 after purchasing an additional 3,833 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Diplomat Pharmacy by 46.7% during the 2nd quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock worth $130,000 after purchasing an additional 2,794 shares in the last quarter. Finally, Sei Investments Co. bought a new stake in Diplomat Pharmacy during the 3rd quarter worth approximately $139,000. 70.60% of the stock is owned by institutional investors and hedge funds.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.